14 min listen
Chemotherapy Response Score in Ovarian Cancer with Alejandra Martinez
FromIJGC Podcast
ratings:
Length:
33 minutes
Released:
Aug 1, 2022
Format:
Podcast episode
Description
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Alejandra Martinez to discuss the Chemotherapy Response Score (CRS) in ovarian cancer. Prof. Martinez has been the Deputy Head of the Surgical Oncology Department at Toulouse University Cancer Center (Institut Universitaire du Cancer de Toulouse) since 2016. She has served as the Director of the ESGO fellowship program of the IUCTO since 2017 and as a professor in oncology since 2021.
Highlights:
- CRS is an easy and reproductible biomarker that can help to stratify a patient's treatment.
- CRS 1-2 is associated with higher tumor load, more extensive surgical procedures, residual tumor after cytoreduction, and early relapse.
- Pathology response measured by the CRS is associated with disease-free and overall survival in patients with stage IIIC/IV treated with neoadjuvant chemotherapy irrespective of the number of cycles.
Highlights:
- CRS is an easy and reproductible biomarker that can help to stratify a patient's treatment.
- CRS 1-2 is associated with higher tumor load, more extensive surgical procedures, residual tumor after cytoreduction, and early relapse.
- Pathology response measured by the CRS is associated with disease-free and overall survival in patients with stage IIIC/IV treated with neoadjuvant chemotherapy irrespective of the number of cycles.
Released:
Aug 1, 2022
Format:
Podcast episode
Titles in the series (100)
The Use of Parp Inhibitors in Advanced Ovarian Cancer with Robert Coleman: In this episode of the IJGC podcast, Editor-in-Ch… by IJGC Podcast